WHO Press Release - January 21, 2004

The new policy guidelines define activities necessary to address the dual epidemic of TB and HIV and gives clear guidance for countries on the circumstances under which these effective activities need to be carried out. It will give critical support for '3 by 5', the WHO plan to provide antiretroviral (ARV) treatment to three million people living with AIDS by the end of 2005.

"TB/HIV is a deadly combination and needs to be tackled with an approach treating the whole person," said Dr. LEE Jong-wook, Director-General of the World Health Organization. "With effective treatment, TB can be cured, HIV managed, and the health of millions of people preserved."

A key element will be to rapidly expand voluntary HIV testing and counselling in TB programmes, with the aim of identifying and referring more than half a million TB patients who are HIV positive for ARV treatment in the next two years. With additional training for health workers, TB programmes will also assist in HIV prevention, ARV distribution and patient care.

At the same time, TB case-finding will be intensified in high HIV prevalence settings by introducing screening and testing for tuberculosis into HIV/AIDS service delivery points. In Africa, up to half of all people with HIV/AIDS develop TB, and up to 80% of tuberculosis patients are HIV infected.

By routinely screening and testing people with HIV/AIDS for TB, co-infected cases, without TB disease, can be treated with prophylactic drugs that prevent development of active tuberculosis, and cured if they already have it. This will prolong the lives of people with HIV/AIDS until they can benefit from the expanded availability of ARVs in the coming years.

UNAIDS Executive Director, Dr. Peter Piot, said: "TB is perhaps the greatest and most deadly opportunistic infection associated with AIDS. By tackling TB and HIV together, we can have a significant impact on improving the quality of life of people infected with HIV, while also controlling TB and preventing new infections."

The vast majority of HIV-infected people do not know their HIV status and seek health care from general service providers. HIV testing and counselling for TB patients using rapid tests offers an entry point for a continuum of prevention, care, support and treatment for HIV/AIDS as well as for tuberculosis.

"Evidence has shown that the uptake of HIV testing by TB patients is high, so mainstreaming HIV testing and counselling into TB programmes will identify many more candidates for ARV treatment," said Dr. Mario Raviglione, the Director of WHO's Stop TB Department. "We also know that ARVs reduce the development of TB in people with HIV, in some cases by up to 80%. So promoting and expanding a collaborative approach makes perfect sense."

The launch of the "Interim Policy on Collaborative TB/HIV Activities" guidelines coincides with the fourth round call for proposals by the Global Fund to Fight AIDS, TB and Malaria. The deadline for submissions is April 2004. The interim policy will enhance proposals which address the dual epidemic of TB and HIV. Already, the Global Fund has committed US$ 2.1 billion over two years to programmes in 120 countries.

Taken together, the two epidemics represent a massive challenge to public health. Forty million people are currently infected with HIV, and 5 million more are infected every year. According to WHO, one third of the world's population is now infected with the TB bacillus, with more than 8 million people developing the active disease and 2 million dying of it each year.

----------------------------------------------

For further information contact: Michael Luhan, Communications Adviser, Stop TB Partnership Secretariat, Tel: +4122 791 1379; mobile: +4179 509 0643; E-mail: luhanm@who.int or Glenn Thomas, Communications Officer, Stop TB Department, WHO, Tel: +4122 791 13983; mobile: +4179 509 0677; E-mail: thomasg@who.int or Andy Seale, Advocacy Adviser, UNAIDS, Tel: +4122 791 4765; Mobile: +4179 250 1693; E-mail: sealea@unaids.org.

040121
UN040104

Copyright © 2004 - Joint United Nations Programme on HIV/AIDS (UNAIDS). All rights reserved. UNAIDS articles, which are not formal publications of UNAIDS, may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The documents may not be sold or used in conjunction with commercial purposes without prior written approval from UNAIDS (contact: UNAIDS Information Centre).

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .